The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses

• Main Authors: Joanna Parkinson (Author), Jesper Sundell (Author), Dinko Rekić (Author), Karin Nelander (Author), Hans Ericsson (Author), Ahmad Ebrahimi (Author), Corina Dota (Author), Mikael Sunnåker (Author)
• Formato: Livro
• Publicado em: Wiley, 2024-04-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Mitiperstat is a myeloperoxidase inhibitor in clinical development for treatment of patients with heart failure and preserved or mildly reduced ejection fraction, non‐alcoholic steatohepatits and chronic obstructive pulmonary disease. We aimed to assess the risk of QT‐interval prolongation...